Simulations Plus, Inc. (SLP) EPS Estimated At $0.11

March 14, 2018 - By Hazel Jackson

 Simulations Plus, Inc. (SLP) EPS Estimated At $0.11
Investors sentiment increased to 2.06 in Q3 2017. Its up 0.54, from 1.52 in 2017Q2. It is positive, as 1 investors sold Simulations Plus, Inc. shares while 17 reduced holdings. 16 funds opened positions while 21 raised stakes. 5.43 million shares or 5.64% more from 5.14 million shares in 2017Q2 were reported.
Legal General Public Ltd Company stated it has 1,570 shares or 0% of all its holdings. Telos Cap Management holds 0.06% or 10,724 shares. California State Teachers Retirement System, California-based fund reported 18,000 shares. Denali Advsr Ltd Liability Company owns 407 shares. California Employees Retirement Systems stated it has 0% in Simulations Plus, Inc. (NASDAQ:SLP). Menta Ltd Llc holds 70,267 shares. 960 were reported by Ameritas Investment Ptnrs. Northern Tru Corp owns 146,924 shares. Ranger Investment Management L P holds 0.26% of its portfolio in Simulations Plus, Inc. (NASDAQ:SLP) for 221,455 shares. Geode Cap Mngmt Lc owns 82,572 shares for 0% of their portfolio. New York State Common Retirement Fund accumulated 0% or 11,600 shares. 148 are held by Federated Inc Pa. Schwab Charles Inv Management holds 0% of its portfolio in Simulations Plus, Inc. (NASDAQ:SLP) for 19,500 shares. Granite Inv Partners Lc has invested 0.14% in Simulations Plus, Inc. (NASDAQ:SLP). Group has invested 0% in Simulations Plus, Inc. (NASDAQ:SLP).

Since September 27, 2017, it had 0 insider purchases, and 3 sales for $887,166 activity.

Analysts expect Simulations Plus, Inc. (NASDAQ:SLP) to report $0.11 EPS on April, 9.They anticipate $0.04 EPS change or 57.14 % from last quarter’s $0.07 EPS. SLP’s profit would be $1.90M giving it 36.36 P/E if the $0.11 EPS is correct. After having $0.10 EPS previously, Simulations Plus, Inc.’s analysts see 10.00 % EPS growth. The stock decreased 2.44% or $0.4 during the last trading session, reaching $16. About 38,288 shares traded. Simulations Plus, Inc. (NASDAQ:SLP) has risen 48.65% since March 14, 2017 and is uptrending. It has outperformed by 31.95% the S&P500.

Simulations Plus, Inc. develops and sells drug discovery and development software for mechanistic modeling and simulation. The company has market cap of $276.68 million. The firm offers GastroPlus, which simulates the absorption, pharmacokinetics , and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It has a 45.71 P/E ratio. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor.

More notable recent Simulations Plus, Inc. (NASDAQ:SLP) news were published by: which released: “DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym® Version 7A” on January 11, 2018, also with their article: “Simulations Plus’ (SLP) CEO Walt Woltosz on Q4 2017 Results – Earnings Call …” published on November 15, 2017, published: “Simulations Plus Launches Version 2.0 of PKPlusâ„¢” on February 01, 2018. More interesting news about Simulations Plus, Inc. (NASDAQ:SLP) were released by: and their article: “Simulations Plus Releases MembranePlusâ„¢ Version 2” published on August 23, 2017 as well as‘s news article titled: “Simulations Plus Announces Senior Management Changes” with publication date: August 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: